• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/6/25 7:21:40 AM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XERS alert in real time by email
    xers-20250306
    ☐000186709600018670962025-03-062025-03-06


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 6, 2025


    XERIS BIOPHARMA HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)
    Delaware001-4088087-1082097
    (State or other jurisdiction of
    incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)

    1375 West Fulton Street, Suite 1300
    Chicago, Illinois 60607
    (Address of principal executive offices, including zip code)

    (844) 445-5704
    (Registrant's telephone number, including area code)

    (Not applicable)
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.0001 per shareXERSThe Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 2.02 Results of Operations and Financial Condition.
    On March 6, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
    The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01    Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit Number
    Description
    99.1
    Press release, dated March 6, 2025, regarding the Company's fourth quarter and full year 2024 financial results
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: March 6, 2025Xeris Biopharma Holdings, Inc.
    By:/s/ Steven M. Pieper
    Name: Steven M. Pieper
    Title: Chief Financial Officer





    Get the next $XERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XERS

    DatePrice TargetRatingAnalyst
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    3/28/2024$5.00Outperform
    Oppenheimer
    8/28/2023$4.50Buy
    Craig Hallum
    10/21/2022$4.00Buy
    Jefferies
    4/28/2022$6.50Buy
    Craig Hallum
    2/16/2022$8.00 → $6.00Outperform
    SVB Leerink
    12/31/2021$6.00 → $8.00Outperform
    SVB Leerink
    12/31/2021$4.25 → $5.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $XERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

      Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X

      2/24/25 8:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Announces CEO Succession Plan

      John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20

      7/8/24 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services

    $XERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Xeris Biopharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00

      11/11/24 7:52:12 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Xeris Biopharma with a new price target

      Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00

      3/28/24 7:52:34 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Xeris Biopharma with a new price target

      Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.50

      8/28/23 7:53:14 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Financials

    Live finance-specific insights

    See more

    $XERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $XERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

      Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou

      3/6/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Mcculloch Kevin covered exercise/tax liability with 733 shares, decreasing direct ownership by 0.04% to 1,683,585 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      4/3/25 4:20:05 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brady James Aloysius was granted 100,000 shares (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      3/28/25 4:45:00 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Brady James Aloysius

      3 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      3/28/25 4:44:04 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,147 worth of shares (4,515 units at $2.25) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/13/24 4:15:08 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,134 worth of shares (4,285 units at $2.37) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/12/24 6:28:50 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schmid John P. bought $10,314 worth of shares (5,400 units at $1.91) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      5/10/24 4:04:26 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Xeris Biopharma Holdings Inc.

      10-Q - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/8/25 4:12:34 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/8/25 7:22:16 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xeris Biopharma Holdings Inc.

      DEFA14A - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      4/23/25 5:02:10 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 5:17:37 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Xeris Biopharma Holdings Inc. (Amendment)

      SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 4:34:36 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      1/26/24 4:23:46 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care